1. Search Result
Search Result
Results for "

autoimmunity

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

7

Peptides

2

Inhibitory Antibodies

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131341

    Syk Inflammation/Immunology Cancer
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers .
    Syk-IN-4
  • HY-P5011

    Somatostatin Receptor Inflammation/Immunology Cancer
    Cortistatin-17 (human) is a somatostatin neuropeptide with potential for studying diseases such as cancer, inflammation, autoimmunity, fibrosis, and pain .
    Cortistatin-17 (human)
  • HY-P5014

    Somatostatin Receptor Inflammation/Immunology Cancer
    Cortistatin-29 (human) is a somatostatin neuropeptide with potential for studying diseases such as cancer, inflammation, autoimmunity, fibrosis, and pain .
    Cortistatin-29 (human)
  • HY-18667

    Phosphatase Inflammation/Immunology
    LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM. LTV-1 has the potential for autoimmunity treatment .
    LTV-1
  • HY-134581A
    Enpatoran hydrochloride
    5 Publications Verification

    M5049 hydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology
    Enpatoran (M5049) hydrochloride is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran hydrochloride is inactive against TLR3, TLR4 and TLR9. Enpatoran hydrochloride can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran hydrochloride exhibits excellent pharmacokinetic properties in vivo. Enpatoran hydrochloride can be used for both innate and adaptive autoimmunity blocking research .
    Enpatoran hydrochloride
  • HY-134581
    Enpatoran
    5 Publications Verification

    M5049

    Toll-like Receptor (TLR) Inflammation/Immunology
    Enpatoran (M5049) is a potent, orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran exhibits excellent pharmacokinetic properties in vivo. Enpatoran can be used for both innate and adaptive autoimmunity blocking research .
    Enpatoran
  • HY-119494

    Others Inflammation/Immunology
    Commendamide is a GPCR G2A/GPR132 agonist (EC50: 11.8 μM). Commendamide can be used for research of autoimmunity and atherosclerosis .
    Commendamide
  • HY-123956

    IRAK Inflammation/Immunology
    HG-12-6 is a type II inhibitor of IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. HG-12-6 can modulate IRAK4 activity in autoimmunity and inflammation .
    HG-12-6
  • HY-153900

    Toll-like Receptor (TLR) Cancer
    TLR8 agonist 6 (Compound A) is a TLR8 agonist, with an EC50 of 0.052 μM. TLR8 agonist 6 induces IL-12p40 production in human PBMC (EC50: 0.031 μM). TLR8 agonist 6 can be used in the research of virus resistance, infection resistance, autoimmunity, tumor, etc .
    TLR8 agonist 6
  • HY-18725

    P2X Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    P2X7-IN-2 (compound 58) is a P2X7 receptor inhibitor. P2X7-IN-2 inhibits IL-Iβ release with an IC50 value of 0.01 nM. P2X7-IN-2 can be used for the research of autoimmunity, inflammation and cardiovascular disease .
    P2X7-IN-2
  • HY-18725A

    P2X Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    P2X7-IN-2 TFA (compound 58) is a P2X7 receptor inhibitor. P2X7-IN-2 TFA inhibits IL-Iβ release with an IC50 value of 0.01 nM. P2X7-IN-2 TFA can be used for the research of autoimmunity, inflammation and cardiovascular disease .
    P2X7-IN-2 TFA
  • HY-12807
    FIPI
    4 Publications Verification

    5-Fluoro-2-indolyl deschlorohalopemide

    Phospholipase Autophagy Inflammation/Immunology Cancer
    FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research .
    FIPI
  • HY-12807A

    5-Fluoro-2-indolyl deschlorohalopemide hydrochloride

    Phospholipase Autophagy Inflammation/Immunology Cancer
    FIPI (5-Fluoro-2-indolyl des-chlorohalopemide) hydrochloride, a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI hydrochloride inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI hydrochloride has the potential for autoimmunity and cancer metastasis research .
    FIPI hydrochloride
  • HY-114504

    Epigenetic Reader Domain Inflammation/Immunology
    RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models .
    RVX-297
  • HY-151093
    IDO2-IN-1
    1 Publications Verification

    Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology
    IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC50 value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research .
    IDO2-IN-1
  • HY-114388
    QM385
    2 Publications Verification

    Others Inflammation/Immunology
    QM385 is a potent sepiapterin reductase (SPR) inhibitor with an IC50 of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability .
    QM385
  • HY-P990041

    CTLA-4 Inflammation/Immunology Cancer
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
    Firastotug
  • HY-148317

    PI3K Inflammation/Immunology
    PI3Kγ inhibitor 6 (compound 9) is a PI3Kγ inhibitor. PI3Kγ inhibitor 6 can be used for the research of inflammatory and autoimmune diseases .
    PI3Kγ inhibitor 6
  • HY-A0124A
    Sapropterin dihydrochloride
    1 Publications Verification

    (6R)-BH4 dihydrochloride; (6R)-Tetrahydro-L-biopterin dihydrochloride

    Others Metabolic Disease Inflammation/Immunology
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin dihydrochloride
  • HY-B1253

    Mechlorethamine hydrochloride

    Others Cancer
    Chlormethine hydrochloride is a foaming agent that causes necrotic and irritating damage to mucous membranes. Used as an antitumor agent in Hodgkin's disease and lymphoma.
    Chlormethine hydrochloride
  • HY-P5182

    Potassium Channel Inflammation/Immunology
    HsTX1, from the scorpion Heterometrus spinnifer, is a 34-residue, C-terminally amidated peptide cross-linked by four disulfide bridges. HsTX1, an the inhibitor of potassium channel, with IC50 for Kv1.3 of 12 pM inhibits TEM cell activation and attenuates inflammation in autoimmunity .
    HsTX1
  • HY-A0124AR

    Others Metabolic Disease Inflammation/Immunology
    Sapropterin (dihydrochloride) (Standard) is the analytical standard of Sapropterin (dihydrochloride). This product is intended for research and analytical applications. Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU) .
    Sapropterin dihydrochloride (Standard)
  • HY-120934
    C25-140
    Maximum Cited Publications
    14 Publications Verification

    TNF Receptor E1/E2/E3 Enzyme Inflammation/Immunology
    C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity .
    C25-140
  • HY-P5182A

    Potassium Channel Inflammation/Immunology
    HsTX1 (TFA) toxin, from the scorpion Heterometrus spinnifer, is a 34-residue, C-terminally amidated peptide cross-linked by four disulfide bridges. HsTX1 (TFA) is an the inhibitor of potassium channel, with IC50 for Kv1.3 of 12 pM and inhibits TEM cell activation and attenuates inflammation in autoimmunity .
    HsTX1 TFA
  • HY-108738

    Zenapax; Ro 24-7375

    Interleukin Related Inflammation/Immunology Cancer
    Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research .
    Daclizumab
  • HY-15091

    LF-150195

    Others Neurological Disease
    Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity .
    Anisperimus
  • HY-B0256
    Azathioprine
    5 Publications Verification

    BW 57-322

    Apoptosis Inflammation/Immunology Cancer
    Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis .
    Azathioprine
  • HY-B0256A

    BW 57-322 sodium

    Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Azathioprine (BW 57-322) sodium is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis .
    Azathioprine sodium
  • HY-B0256R

    Apoptosis Inflammation/Immunology Cancer
    Azathioprine (Standard) is the analytical standard of Azathioprine. This product is intended for research and analytical applications. Azathioprine (BW 57-322) is an orally active immunosuppressive agent. Azathioprine can be converted in vivo to the active metabolite 6-mercaptopurine (6-MP). Azathioprine has myelosuppressive effects and induces apoptosis .
    Azathioprine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: